APTO Aptose Biosciences Inc.

2.26
-0.07  -3%
Previous Close 2.33
Open 2.31
Price To Book 6.3
Market Cap 85265213
Shares 37,771,424
Volume 223,528
Short Ratio
Av. Daily Volume 242,005

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b clinical hold released June 29, 2018. First patient of re-initiation announced November 26, 2018. To be completed in 2019.
APTO-253
Acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)

Latest News

  1. Aptose Presents Highlights From CG-806 KOL Event
  2. OHSU and Aptose Present New CG-806 Preclinical Data at ASH 60th Annual Meeting
  3. Aptose Presents New Preclinical Data on CG-806 PAN-FLT3/PAN-BTK Inhibitor at ASH 60th Annual Meeting
  4. Aptose Biosciences Doses First Patient in Re-Initiation of Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological Malignancies
  5. Aptose to Participate in Upcoming Investor Conferences, Host Key Opinion Leader Event, and Present Data at the Upcoming ASH Meeting
  6. New Research: Key Drivers of Growth for WellCare Health Plans, Streamline Health Solutions, Aptose Biosciences, Houston Wire & Cable, RTI Surgical, and Atlantica Yield — Factors of Influence, Major Initiatives and Sustained Production
  7. Aptose Biosciences: 3Q Earnings Snapshot
  8. Aptose Reports Results for the Third Quarter Ended September 30, 2018
  9. Aptose to Present New CG-806 Data at the 2018 ASH Annual Meeting
  10. Aptose to Release Third Quarter Ended September 30, 2018 Financial Results on November 6, 2018
  11. Aptose Biosciences and CrystalGenomics Announce Issuance of European Patent for CG-806
  12. Aptose to Present at Upcoming Investor Conferences in October 2018
  13. Breaking Down Aptose Biosciences Inc’s (TSE:APS) Ownership Structure
  14. New Strong Sell Stocks for July 27th